JUL 22 2026
GSK — Jideytro (zidesamtinib) $GSK
for TKI-pretreated advanced ROS1-positive non-small cell lung cancer
About
Jideytro is a selective ROS1 inhibitor designed to penetrate the central nervous system. It works by blocking the activity of the ROS1 protein, a key driver of cancer growth in certain lung tumors. This targeted approach may offer a treatment option for patients whose cancer has progressed on prior therapies.
Drug Watch — recent news on Jideytro
- Jideytro Shrank Tumors in 94% of Patients With ROS1-Positive Lung Cancer - Cure Today
- GSK targets first-line use for newly-acquired lung cancer drug Jideytro - The Pharma Letter
- GSK Presents Jideytro Data for Potential Use in First-Line NSCLC - Yahoo Finance
- GSK Presents Jideytro Data for Potential Use in First-Line NSCLC - Eastern Progress
- GSK lines up first-line filing push for Jideytro in ROS1-positive lung cancer - Dealroom.co